Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Cephalalgia. 2017 Oct 12;38(8):1471–1484. doi: 10.1177/0333102417737778

Figure 4.

Figure 4

VL-102 produces periorbital allodynia that is blocked by migraine medications. C57Bl/6J mice were treated every other day with vehicle or VL-102 (1 mg/kg, IP) for 9 days. (A) Basal responses, as assessed prior to vehicle or VL-102 administration, significantly decreased in groups receiving VL-102. p<0.01 effect of group, time and interaction, 2-way RM ANOVA and Holm-Sidak post-hoc analysis. (B) VL-102 produced significant periorbital allodynia in mice tested 2 hours post-drug or vehicle administration. p<0.001 effect of group only, 2-way RM ANOVA and Holm-Sidak post-hoc analysis. n=8/group. (C) Sumatriptan (0.6 mg/kg, IP) significantly inhibited periorbital allodynia evoked by VL-102 (1 mg/kg, IP). p<0.01 group, drug, and interaction, 2-way ANOVA and Holm-Sidak post-hoc analysis. **p<0.01 as compared to VEH-VEH, ***p<0.001 as compared to VL-102-VEH, n=5-6/group. (D,E) Mice were treated with vehicle (VEH) or propranolol (20 mg/kg IP) daily for 11 days. On day 9 basal responses were determined (D), and mice were injected with either vehicle (VEH) or VL-102 (1 mg/kg, IP). p<0.05 effect of group, drug, and interaction, 2-way ANOVA and Holm-Sidak post-hoc analysis. **p<0.01 as compared to VEH-VEH, and ***p<0.001 as compared to VEH-VL-102 controls. (E) Post-treatment responses were assessed 2h following VL-102 administration. p<0.001 effect of group, but no significant effect of time or interaction, 2-way ANOVA. n=6/group.